Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn

RALEIGH, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Slate Medicines (Slate), a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the appointment of Mark W. Hahn to the company's Board of Directors. Mr. Hahn brings more than 25 years of leadership experience building and scaling life sciences companies.